Elsevier

Maturitas

Volume 30, Issue 1, 20 September 1998, Pages 27-36
Maturitas

Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease

https://doi.org/10.1016/S0378-5122(98)00056-5Get rights and content

Abstract

Hormone replacement therapy (HRT) in postmenopausal women is associated with a reduction in the risk of developing coronary artery disease (CAD) of about 50%. Women with an elevated risk for CAD appear to benefit most by HRT. The HRT-associated cardiovascular protection may be related to favourable changes in several important cardiovascular risk estimators, such as circulating blood concentrations of cholesterol, lipoprotein(a) (Lp(a)) and homocysteine. This paper reviews the literature presently available on the effects of HRT on cholesterol, Lp(a) and homocysteine concentrations, and special attention will be given to the effects on their elevated concentrations. The effect of HRT in women with hypertension is reviewed as well. From this overview it can be concluded that risk factors such as cholesterol, Lp(a), and homocysteine can be favourably modulated by HRT, and especially, that the strongest reductions can be achieved in those women with the highest concentrations. Although clinical trials still need to demonstrate the impact of lowering concentrations of Lp(a) and homocysteine, HRT appears to be a promising risk reduction strategy in this respect.

Introduction

In industrialised countries coronary artery disease (CAD) is the major cause of death in women. The mortality rate from CAD is about 3–4 fold that related to cancer. The risk of developing atherothrombotic CAD is associated with various factors. Modulation of these factors is a potential tool for the primary and secondary prevention of CAD, and may therefore be of great importance for the cardiovascular health in the individual, but it may also have a substantial socio-economic impact.

In women as compared to men, the incidence of CAD is low before the age of 50. In contrast, in women older than 50, CAD risk strongly increases, indicating that the postmenopausal oestrogen deficiency state is a major risk factor in the development of CAD. Moreover, young ovariectomised women also suffer from an increased risk of dying from CAD [1], which supports the hypothesis that loss of ovarian function increases CAD risk.

Accumulating evidence supports the suggested cardiovascular protective role of postmenopausal hormone replacement therapy (HRT) 2, 3. Many epidemiological studies and several meta-analyses have reported a 50% lower incidence of CAD in oestrogen users compared with non-users [4], and comparable data have recently been published for combined oestrogen–progestogen users [5]. In addition, experimental studies in monkeys [6], in rabbits and rats have demonstrated that hormone administration reduces the arterial cholesterol accumulation.

The cardiovascular protective influence of HRT appears to be of special benefit in women at high risk for CAD 7, 8, 9, 10, 11, 12. In the Lipid Research Clinic study, Bush et al. [7]reported a stronger reduction in CAD mortality in oestrogen-using hyperlipidaemic women compared with oestrogen-using normo-lipidaemic women. Ross et al. [8]demonstrated, in oestrogen-using women, that CAD mortality was relatively more reduced in heavy smokers when compared with non-smoking women. Ten-year mortality in oestrogen-using versus non-using women with angiographically proven CAD was more reduced in women with severe coronary stenosis than in women with normal angiography [9].

Section snippets

Risk factors

An increasing number of factors have been identified which influence the risk of developing CAD. For many years, most attention was given to the impact on CAD risk due to changes in serum lipids and lipoproteins, and it was demonstrated that postmenopausal women have a more atherogenic lipid profile when compared with premenopausal women. Furthermore, HRT was found to have favourable effects on the lipid profile reflected by a reduction in the atherogenic LDL-cholesterol and an increase in the

Blood pressure

The effects of HRT on blood pressure have scarcely been investigated. Most studies have reported no change or a small decrease in systolic and diastolic blood pressures 13, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91. Proposed mechanisms to explain these observations are vasodilation [92], possibly related to calcium antagonistic effects of oestrogens [93], and inhibition of the angiotensin-converting-enzyme [94].

Conclusions

Based on the literature presently available, there is strong evidence that cholesterol, Lp(a) and homocysteine, as important predictors for occlusive arterial disease, can be favourably modulated by HRT, and that the strongest reductions can be achieved in women with the highest concentrations.

Although clinical trials still need to demonstrate the impact of lowering concentrations of homocysteine and Lp(a), HRT appears to be a promising risk reduction strategy in this respect.

References (94)

  • RA Lobo et al.

    Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, excercise, and estrogen

    Am J Obstet Gynecol

    (1992)
  • MJ Van der Mooren et al.

    A 2-year study on the beneficial effects of 17β-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone

    Eur J Obstet Gynecol Reprod Biol

    (1993)
  • D Crook et al.

    Lipoprotein(a) levels are reduced by danazol, an anabolic steroid

    Atherosclerosis

    (1992)
  • G Alfthan et al.

    Plasma homocysteine and cardiovascular disease mortality

    Lancet

    (1997)
  • MJ Van der Mooren et al.

    The effects of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women

    Fertil Steril

    (1997)
  • V Mijatovic et al.

    Postmenopausal oral 17β-oestradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels

    Fertil Steril

    (1998)
  • V Mijatovic et al.

    A randomized controlled study of the effects of 17β-oestradiol-dydrogesterone on plasma homocysteine in postmenopausal women

    Obstet Gynecol

    (1998)
  • A Pines et al.

    Exercise echocardiography in postmenopausal hormone users with mild systemic hypertension

    Am J Cardiol

    (1996)
  • AA Akkad et al.

    Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy

    Obstet Gynecol

    (1997)
  • P Collins et al.

    Cardiovascular protection by oestrogen—a calcium antagonist effect?

    Lancet

    (1993)
  • AJ Proudler et al.

    Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women

    Lancet

    (1995)
  • MJ Stampfer et al.

    Menopause and heart disease: a review

    Ann NY Acad Sci

    (1990)
  • F Grodstein et al.

    Postmenopausal estrogen and progestin use and the risk of cardiovascular disease

    New Engl J Med

    (1996)
  • JK Williams et al.

    Regression of atherosclerosis in female monkeys

    Arterioscler Thromb Vasc Biol

    (1995)
  • TL Bush et al.

    Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study

    Circulation

    (1987)
  • RK Ross et al.

    Menopausal oestrogen therapy and protection from death from ischaemic heart disease

    Lancet

    (1981)
  • JM Sullivan et al.

    Estrogen replacement and coronary artery disease: effects on survival in postmenopausal women

    Arch Intern Med

    (1990)
  • KM Newton et al.

    Estrogen replacement therapy and prognosis after first myocardial infarction

    Am J Epidemiol

    (1997)
  • Postmenopausal Estrogen/Progestin Intervention Trial Writing Group

    Effects of estrogen/progestin regimen in heart disease risk factors in postmenopausal women

    J Am Med Assoc

    (1995)
  • V Mijatovic et al.

    The effects of oestrogens on vessel wall and cardiac function, haemostasis and homocysteine metabolism

    Eur Menopause J

    (1996)
  • MJ Van der Mooren et al.

    The cardiovascular risk profile: influence of menopausal status and postmenopausal HRT

    Gynaecology Forum

    (1996)
  • HE Brussaard et al.

    Short-term oestrogen replacement therapy improves resistance, lipids and fibrinolysis in postmenopausal women with NIDDM

    Diabetologica

    (1997)
  • HE Brussaard et al.

    Effect of 17β-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus

    Arterioscler Thromb Vasc Biol

    (1997)
  • RA Lobo

    Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women

    J Clin Endocrinol Metab

    (1991)
  • G Samsioe

    Lipid profiles in estrogen users

  • G Samsioe et al.

    Transdermal oestradiol plus medroxyprogesteron acetate lowers cholesterol in moderately hypercholesterolemic women

    Maturitas

    (1966)
  • MJ Tikkanen et al.

    Natural oestrogen as an effective treatment for type-II hyperlipoproteinaemia in postmenopausal women

    Lancet

    (1978)
  • J Slowinska-Srzednicka et al.

    Effects of transdermal 17β-oestradiol combined with oral progestogen on lipids and lipoproteins in hypercholesterolaemic postmenopausal women

    J Int Med

    (1993)
  • Tonstad S, Ose L, Görbitz C, Djoseland, Bard JM, Fruchart JC. Efficacy of sequential hormone replacement therapy in the...
  • GM Darling et al.

    Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women

    New Engl J Med

    (1997)
  • MH Davidson et al.

    A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women

    Arch Int Med

    (1997)
  • G Hoefler et al.

    Lipoprotein(a): a risk factor for myocardial infarction

    Arteriosclerosis

    (1988)
  • AM Scanu et al.

    Lipoprotein(a) and atherosclerosis

    Ann Intern Med

    (1991)
  • VMG Maher et al.

    Lipoprotein(a) and coronary heart disease

    Curr Opin Lipidol

    (1995)
  • L Berglund

    Diet and drug therapy for lipoprotein(a)

    Curr Opin Lipidol

    (1995)
  • J Heinrich et al.

    Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population

    Clin Chem

    (1991)
  • CJ Kim et al.

    Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy

    Arch Intern Med

    (1996)
  • Cited by (0)

    View full text